Improved Diagnosis of Rheumatoid Arthritis due to Biomarker
Published By : 28 Aug 2014 | Published By : QYRESEARCH
The diagnosis rheumatoid arthritis may become a little easy for physicians because of a new type of biomarker. Biomarker refers to a certain measurable indicator of a physical/biological condition. According to research, unlike the traditional antibody-serum testing techniques, the identification of blood-serum levels of 14-3-3eta protein, exhibits better diagnosis of rheumatoid arthritis. The ideal combination is however, when the conventional technique of antibody testing is supplemented with this biomarker.
According to the findings of Quest Diagnostics, about 65% of patients suffering from rheumatoid arthritis showed positive result for 14-3-3eta as against the current biomarkers of 57% for rheumatoid factor and 59% for anticitrullinated peptide antibodies.
After comparative analysis of all the three biomarkers, it was observed that about 96% of the established rheumatoid arthritis patients and about 78% of the early rheumatoid arthritis patients were identified.
The patients in whom the rheumatoid factor and anticitrullinated peptide antibodies results were negative, the 14-3-3eta test identified 67% patients with rheumatoid arthritis and 21% patients with early signs of rheumatoid arthritis. Precise diagnosis is possible when the 14-3-3eta test is supplemented with established biomarkers.
Rheumatoid arthritis refers to an autoimmune disorder that according to reports, affects about 1.3 million American adults. In this bodily disorder, the immune system attacks the body’s own tissues particularly the membranes lining the joints. Fluids get coagulated in the joints resulting in systemic inflammation and excruciating pain.
The initial symptoms of rheumatoid are generally subtle which may lead to delayed diagnosis. Doctors and researchers have stated that rheumatoid arthritis treatments should ideally start within 12 weeks of the symptoms in order to prevent joint damage and ensure long term patient prognosis.